Biology of myocardial recovery in advanced heart failure with long-term mechanical support.


Journal

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
ISSN: 1557-3117
Titre abrégé: J Heart Lung Transplant
Pays: United States
ID NLM: 9102703

Informations de publication

Date de publication:
10 2022
Historique:
received: 13 12 2021
revised: 03 07 2022
accepted: 07 07 2022
pubmed: 15 8 2022
medline: 5 10 2022
entrez: 14 8 2022
Statut: ppublish

Résumé

Cardiac remodeling is an adaptive, compensatory biological process following an initial insult to the myocardium that gradually becomes maladaptive and causes clinical deterioration and chronic heart failure (HF). This biological process involves several pathophysiological adaptations at the genetic, molecular, cellular, and tissue levels. A growing body of clinical and translational investigations demonstrated that cardiac remodeling and chronic HF does not invariably result in a static, end-stage phenotype but can be at least partially reversed. One of the paradigms which shed some additional light on the breadth and limits of myocardial elasticity and plasticity is long term mechanical circulatory support (MCS) in advanced HF pediatric and adult patients. MCS by providing (a) ventricular mechanical unloading and (b) effective hemodynamic support to the periphery results in functional, structural, cellular and molecular changes, known as cardiac reverse remodeling. Herein, we analyze and synthesize the advances in our understanding of the biology of MCS-mediated reverse remodeling and myocardial recovery. The MCS investigational setting offers access to human tissue, providing an unparalleled opportunity in cardiovascular medicine to perform in-depth characterizations of myocardial biology and the associated molecular, cellular, and structural recovery signatures. These human tissue findings have triggered and effectively fueled a "bedside to bench and back" approach through a variety of knockout, inhibition or overexpression mechanistic investigations in vitro and in vivo using small animal models. These follow-up translational and basic science studies leveraging human tissue findings have unveiled mechanistic myocardial recovery pathways which are currently undergoing further testing for potential therapeutic drug development. Essentially, the field is advancing by extending the lessons learned from the MCS cardiac recovery investigational setting to develop therapies applicable to the greater, not end-stage, HF population. This review article focuses on the biological aspects of the MCS-mediated myocardial recovery and together with its companion review article, focused on the clinical aspects, they aim to provide a useful framework for clinicians and investigators.

Identifiants

pubmed: 35965183
pii: S1053-2498(22)02030-7
doi: 10.1016/j.healun.2022.07.007
pii:
doi:

Types de publication

Journal Article Review Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1309-1323

Subventions

Organisme : NHLBI NIH HHS
ID : K08 HL146964
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL135121
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL156667
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL151924
Pays : United States

Informations de copyright

Copyright © 2022 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.

Auteurs

Eleni Tseliou (E)

Division of Cardiovascular Medicine, University of Utah Health, Salt Lake City, UT; Nora Eccles Harrison Cardiovascular Research and Training Institute, University of Utah Health, Salt Lake City, UT.

Kory J Lavine (KJ)

Division of Cardiology, Washington University School of Medicine, St Louis, MO.

Omar Wever-Pinzon (O)

Division of Cardiovascular Medicine, University of Utah Health, Salt Lake City, UT; Nora Eccles Harrison Cardiovascular Research and Training Institute, University of Utah Health, Salt Lake City, UT.

Veli K Topkara (VK)

Department of Medicine, Division of Cardiology, Columbia University College of Physicians and Surgeons, New York, NY.

Bart Meyns (B)

Department of Cardiology and Department of Cardiac Surgery, University Hospitals Leuven, Leuven, Belgium.

Iki Adachi (I)

Division of Cardiac Surgery, Texas Children's Hospital, Houston, TX.

Daniel Zimpfer (D)

Department of Surgery, Division of Cardiac Surgery, Medical University of Vienna, Vienna, Austria.

Emma J Birks (EJ)

University of Kentucky, Lexington, KY.

Daniel Burkhoff (D)

Department of Medicine, Division of Cardiology, Columbia University College of Physicians and Surgeons, New York, NY; Cardiovascular Research Foundation (CRF), New York, NY.

Stavros G Drakos (SG)

Division of Cardiovascular Medicine, University of Utah Health, Salt Lake City, UT; Nora Eccles Harrison Cardiovascular Research and Training Institute, University of Utah Health, Salt Lake City, UT. Electronic address: stavros.drakos@hsc.utah.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH